Safety of Very Low Low-Density Lipoprotein Cholesterol Levels With Alirocumab: Pooled Data From Randomized Trials.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of the American College of Cardiology"
DOI: 10.1016/j.jacc.2016.11.037
Abstract: BACKGROUND Proprotein convertase subtilisin/kexin type 9 monoclonal antibodies can reduce low-density lipoprotein cholesterol (LDL-C) to very low levels when added to background lipid-lowering therapy. OBJECTIVES The safety of alirocumab was evaluated in patients with at… read more here.
Keywords: density lipoprotein; lipoprotein cholesterol; low density; levels alirocumab ... See more keywords
ON-TREATMENT LDL-C LEVELS WHEN ALIROCUMAB DOSE IS DECREASED FROM 150 TO 75 MG EVERY 2 WEEKS IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA: RESULTS FROM ODYSSEY OLE
Sign Up to like & getrecommendations! Published in 2017 at "Journal of the American College of Cardiology"
DOI: 10.1016/s0735-1097(17)35100-8
Abstract: Background: Alirocumab (ALI) is available in two doses, 75 and 150 mg (to be administered once every 2 weeks [Q2W]). ODYSSEY LONG TERM was a 78-week double-blind trial of ALI 150 mg Q2W versus placebo,… read more here.
Keywords: alirocumab dose; treatment ldl; every weeks; dose decreased ... See more keywords